CN101838245A - 喹唑啉衍生物或其药用盐、制备方法和用途 - Google Patents
喹唑啉衍生物或其药用盐、制备方法和用途 Download PDFInfo
- Publication number
- CN101838245A CN101838245A CN 201010182426 CN201010182426A CN101838245A CN 101838245 A CN101838245 A CN 101838245A CN 201010182426 CN201010182426 CN 201010182426 CN 201010182426 A CN201010182426 A CN 201010182426A CN 101838245 A CN101838245 A CN 101838245A
- Authority
- CN
- China
- Prior art keywords
- alkoxyl group
- quinazoline
- alcohol
- quinazoline derivant
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 241001597008 Nomeidae Species 0.000 title claims abstract description 53
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- -1 quinazoline compound Chemical class 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 7
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000010977 jade Substances 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000003560 cancer drug Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 125000005336 allyloxy group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 150000003246 quinazolines Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract description 42
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract description 41
- 229940084651 iressa Drugs 0.000 abstract description 37
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000460 chlorine Substances 0.000 description 21
- 239000012141 concentrate Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 11
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 8
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 201000005296 lung carcinoma Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 229960002584 gefitinib Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- BWDCBBZUYJDNJZ-UHFFFAOYSA-N quinazolin-7-ol Chemical compound C1=NC=NC2=CC(O)=CC=C21 BWDCBBZUYJDNJZ-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种喹唑啉衍生物或其药用盐、合成方法及其用途。本发明的喹唑啉衍生物具有如下结构式:
Description
技术领域
本发明涉及喹唑啉衍生物或其药用盐、制备方法和用途。它们具有抗癌活性,如对肺癌细胞株NCI-H1975和A549的具有生长抑制作用,尤其可以用于制备治疗对现有的主要抗非小细胞肺癌药物Iressa无法治疗的非小细胞肺癌的药物。
背景技术
攻克癌症一直是医学界面临的重大挑战。随着分子生物学的不断发展,人们对肿瘤发生、发展机制的了解也越来越深入。近年来,与该过程相关的一些特异性蛋白质,如生长因子受体(EGFR)、信号转导分子、细胞周期蛋白、细胞凋亡调节因子、血管内皮生长因子(VEGF)等被相继发现,并且都有可能成为肿瘤治疗的分子靶点,于是学者们提出了肿瘤分子靶向治疗的概念,即利用特异性分子(单克隆抗体、小分子物质)封闭或抑制这些分子靶点,从而抑制肿瘤细胞的生长、转移或诱导其凋亡(褚亮 刘新垣 肿瘤防治杂志 CHIN J CANCER PREVTREAT,October 2005,12(20),1583)。Iressa是一种作用于表皮生长因子受体(EGFR),用于治疗非小细胞肺癌的靶向药物(张力,程中伟,高金明“晚期非小细胞肺癌分子靶向药物研究新进展”,Acta Academiae Medicinae Sinicae,26,3,323-329)。
EGFR(epidural growth factor receptor,表皮生长因子受体)是一种分子量约为170kD的糖蛋白,广泛分布于人体各组织的细胞膜上,它的跨膜区为单向一次性的,故也称为单次跨膜受体。它的胞内区含有酪氨酸激酶段和ATP结合位点,对调节细胞增殖及分化至关重要。目前已发现有3种EGFR突变体:EGFR Ⅰ、EGFR Ⅱ和EGFR Ⅲ,突变一般发生在胞外区,极少发生在跨膜区和胞内区。3种突变体中以EGFR Ⅱ最常见(Campa.M.J.;Kuan.C.T.;O’Connor McCourt.M.D.et al.Design of a novel small peptide targeted against a tumor-specific receptor.Biochem Biophys Res Commun,2000,275(2),631-636)。且EGFR Ⅱ仅表达于肿瘤组织,而在正常组织中不表达,因此其特异性单抗显示了良好的肿瘤靶向治疗前景(Luo.X.,Gong.X.,Tang.C.K.Suppression of EGFR Ⅷ-mediated proliferationand tumorigenesis of breast cancer cells by ribozyme.Int J Cancer,2003,104(6),716-721)。
EGFR酪氨酸激酶抑制剂-Iressa(ZD1839,Gefitinib),是阿斯利康(AstraZeneca)公司生产的一种能口服的小分子苯胺喹唑啉(quinazoline)类化合物该药能进入细胞内,与ATP竞争EGFR的特定结合位点,从而抑制酪氨酸激酶(TK)的活性。研究发现,Iressa通过多种机制发挥抗肿瘤的作用:诱导细胞周期阻滞在G1期;增加凋亡和抑制细胞增殖;抗血管生成和抗转移;逆转肿瘤细胞的耐药性,增强细胞毒性药物的效应(Mendelsohn.J.,Baselga.J.,Statusof epidermal growth factor receptor antagonists in the biology and treatment of cancer.J.Clin.Oncol.,2003,21(14),2787-2799)。此药于2003年5月被美国FDA批准,用于治疗化疗失败的晚期非小细胞肺癌(NSCLC),并于2005年3月在中国获准上市。
Iressa治疗NSCLC的Ⅰ~Ⅲ期临床试验表明,Iressa的近期疗效为15%~20%,不良反应较轻。随机双盲的Ⅲ期IDEAL1和IDEAL2试验表明,IRESSA作为2、3线单药治疗NSCLC的有效率为18.4%,作为3、4线治疗的有效率为11.8%。另外,40%~50%患者的肿瘤无进展,40%以上患者的症状得到明显改善(Kris.M.G.,Natale.R.B.,Herbst.R.S.,et al.Efficacy of gefitinib,an inhibitorof the epidermal growth factor receptor tyrosine kinase,in symptomatic patients withnon-small cell lung cancer:a randomized trial.J.Am.Med.Assoc.,2003,290(16),2149-2158;Fukuoka.M.,Yano.S.,Giaccone.G.,et al.Multi-institutional randomizedphase II trial of gefitinib for previously treated patients with advanced non-small-celllung cancer.J.Clin.Oncol,2003,21(12),2237~2246.)
尽管Iressa之类的EGFR靶向治疗已经成功进入临床应用阶段,但是如前所述,有些患者对这类治疗并不敏感,有些患者对该类药物最终产生耐药性。2004年8月,日本最先报道了3例对Iressa治疗有效的NSCLC患者在经过3~7个月的缓解期后,病情进一步发展(局部复发或远处转移),并称之为发生了获得性耐药(acquired resistance)(Hoshi.S.,Yamaguchi.T.,Recurrence of Non-small-celllung cancer after successful treatment with Gefitinib-report of three cases.Gan ToKagaku Ryoho,2004,31(8),1209-1213)。根据已有的研究资料,进展往往发生于Iressa治疗后稳定或缓解后4~5个月。
针对耐药机制,生物学家们进行了大量的研究,发现胞内许多不同信号通路的改变是引起EGFR抑制剂耐药的主要原因。主要包括以下4方面:(1)肿瘤诱导的非依赖于EGFR的血管生成;(2)绕开EGFR通路的其他TK受体(酪氨酸激酶受体)的活化;(3)胞内EGFR下游信号蛋白非依赖性或组成性活化;(4)EGFR基因突变或靶点缺失(王洪波,陈晓光EGFR抑制剂耐药机制研究的新进展 国际药学研究杂志 2007年10月,34(5),347-350)。
美国Memorial Sloan-Kettering肿瘤中心对6例接受过Iressa 3个月~2年出现疾病进展的NSCLC患者肿瘤标本中,EGFR基因19到21外显子的DNA进行了测序,其中有3例均出现2369位核苷酸替换(C2T),导致酪氨酸激酶活化域790位苏氨酸残基被蛋氨酸取代,而且可以确定,这种突变发生于Iressa治疗开始和发生耐药之间的时间段。有学者认为,790位的野生型苏氨酸残基定位于酪氨酸激酶的催化区域疏水的ATP结合口袋中,而Iressa以喹唑啉环结合于这种亲脂袋中,阻断ATP的结合发挥作用。当苏氨酸被大的蛋氨酸残基取代,可能导致与药物接触的芳香环结构的崩解,但并不影响ATP的结合。另外已有实验结果证明,T790M突变并不会取消野生型EGFR的催化活性。而且,T790M突变可能也影响了激酶的活性或改变了突变型EGFR底物的专一性,从而使带有突变的肿瘤细胞更具有增殖活性(William.P.,Vincent.A.,Miller,et al,Acquired Resistance ofLung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a SecondMutation in the EGFR Kinase Domain.PLOS Medicine,2005,2(3),1-11)。
总而言之,作为一种酪氨酸激酶,EGFR(epidural growth factor receptor,表皮生长因子受体)在多种肿瘤中起着重要的生长、增殖调节作用,是近年来抗肿瘤靶向治疗的一个重要靶点。小分子酪氨酸激酶抑制剂Iressa(Gefitinib,易瑞沙)通过与EGFR结合,能够作为治疗NSCLC(非小细胞肺癌)的抗癌药物,对特别是女性、非吸烟者、腺癌尤其是细支气管肺泡癌、东方人具有很好的治疗效果。但是可能由于EGFR基因突变引起的Iressa耐药性的出现使它的应用受到了一定的限制,并使得对Iressa补充疗法的研究变得尤为迫切。
发明内容
本发明目的是提供一种喹唑啉衍生物或其药用盐;
本发明目的还提供一种上述喹唑啉衍生物或其药用盐的制备方法;
本发明另外一个目的是提供上述喹唑啉衍生物或其药用盐的用途,用于制备治疗肺癌的药物,尤其是用于制备治疗非小细胞肺癌的药物。
本发明的喹唑啉衍生物具有如下的结构式:
其中,n为1,2或3;R1为C1-4的烷氧基;R2各自独立地代表卤素、三氟甲基、C1-4的烷氧基或C1-4的烷氧羰基;R3为二-{C1-4的烷基}-C2-4的烷氧基、,吡咯烷-1-基-C2-4的烷氧基、哌啶子基-C2-4的烷氧基、吗啉代-1-基-C2-4的烷氧基、哌嗪-1-基-C2-4的烷氧基、4-C1-4的烷基哌嗪-1-基-C2-4的烷氧基、咪唑-1-基-C2-4的烷氧基、二-[C1-4的烷氧基-C2-4的烷氧基]氨基-C2-4的烷氧基、硫吗啉代-C2-4的烷氧基、1-氧代硫吗啉代-C2-4的烷氧基或、1,1-二氧代硫吗啉代-C2-4的烷氧基、烯丙氧基或叠氮子基-C2-4的烷氧基。
推荐所述的喹唑啉衍生物具有如下的结构式:
所述的喹唑啉衍生物可以以溶剂化物或非溶剂化物形式,例如水合物形式存在。本发明的喹唑啉衍生物因碱性足够强,与酸加成可以成为喹唑啉衍生物的药用盐,所述酸如盐酸、氢溴酸、硫酸、磷酸、三氟乙酸、枸橼酸、马来酸、酒石酸、富马酸、甲磺酸或4-甲苯磺酸。换言之,本发明的喹唑啉衍生物药用盐是上述结构式喹唑啉衍生物的盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、三氟乙酸盐、枸橼酸盐、马来酸盐、酒石酸盐、富马酸盐、甲磺酸盐或4-甲苯磺酸盐。
特别优选的本发明的喹唑啉衍生物或其药用盐,推荐(R2)n为2’-溴-5’-三氟甲基;R1为甲氧基;R3为3-哌啶代氧基.
本发明喹唑啉衍生物或其药用盐的制备方法,其特征是采用如下(a)和(b)的方法分别获得喹唑啉衍生物;获得的喹唑啉衍生物再通过步骤(c)获得它们的药用盐:
(a)有机溶剂溶剂中和微波下,结构式为的喹唑啉衍生物,结构式为的苯胺和催化量的浓盐酸反应1-30分钟;所述的结构式(2)的喹唑啉化合物、结构式(3)的苯胺的摩尔比为1∶1~2;所述的微波反应功率为150瓦;其中,所述的微波波长为1毫米到1米,反应功率为10瓦到300瓦;所述的Z包括氯原子、溴原子、碘原子、甲氧基、苯氧基、甲磺酰基或甲苯-4-璜酰氧基。
特别优选的本发明的喹唑啉衍生物的制备方法,推荐结构式为的喹唑啉衍生物与结构式为的苯胺和催化量的浓盐酸在微波反应器中反应5-10分钟。所述的微波反应器的波长范围为50毫米到500毫米,反应功率为50瓦到150瓦。
所述的喹唑啉化合物、三苯基膦(PPh3)、偶氮二甲酸二乙酯(DEAD)或偶氮二甲酸二异丙酯(DIAD)和醇的摩尔比为1∶1~5∶1~5∶1~5;所述的醇为吗啉代-(C2-4)醇(或哌嗪-1-基-(C2-4)醇、4-(C1-4)烷基哌嗪-1-基-(C2-4)醇、咪唑-1-基-(C2-4)醇、二-[(C1-4)烷氧基-(C2-4)烷氧基]氨基-(C2-4)醇、硫吗啉代-(C2-4)醇、1-氧代硫吗啉代-(C2-4)醇或1,1-二氧代硫吗啉代-(C2-4)的醇;
(c)有机溶剂中,将步骤(a)或(b)获得的喹唑啉化合物分别和酸反应10-60分钟;所述的喹唑啉化合物与酸的摩尔比为1∶1~100;所述的盐酸、氢溴酸、硫酸、磷酸、三氟乙酸、枸橼酸、马来酸、酒石酸、富马酸、甲磺酸或4-甲苯磺酸。
其中,n、R1、 R2和R3如前1所述;Z为具有离去性能的取代基,包括氯原子、溴原子、碘原子、甲氧基、苯氧基、甲磺酰基或甲苯-4-璜酰氧基。
以上所指的有机溶剂包括但不限于甲醇、乙醇、正丙醇、正丁醇、异丙醇、二氯甲烷、氯仿、1,2-二氯乙烷、四氯化碳、乙醚、四氢呋喃、苯、甲苯、二甲苯、丙酮、丁酮、乙腈、N,N-二甲基甲酰胺或二甲亚砜。
本发明的喹唑啉衍生物的用途,可以用于制备非小细胞肺癌治疗的药物。
研究中使用对现有的肺癌治疗药物Iressa不敏感的体外肺癌细胞株NCI-H1975和肺癌细胞株A549生长抑制实验来评价喹唑啉衍生物的抗癌活性。
本发明利用简便的方法合成了一系列喹唑啉衍生物。使用对现有的肺癌治疗药物Iressa不敏感的体外肺癌细胞株NCI-H1975和肺癌细胞株A549生长抑制实验来评价喹唑啉衍生物的抗癌活性,结果表明许多化合物都表现出了优于Iressa的抗癌活性,很有希望发展为新的抗肿瘤药物,用于对Iressa不敏感的或者已产生耐药性的病例的治疗。
附图说明
图1本发明的部分喹唑啉衍生物的抗癌活性的结果
其中横坐标为喹唑啉衍生物标号,喹唑啉衍生物1a、1b、1c和1d分别对应于实施例1、2、4和5,纵坐标为喹唑啉衍生物作用于对Iressa不敏感的肺癌细胞NCI-H1975时的IC50(μM)(半数抑制浓度)值。喹唑啉衍生物1a、1b、1c和1d具有如下的结构式:
图2本发明的喹唑啉衍生物1a和Iressa分别在对Iressa不敏感的肺癌细胞NCI-H1975和A549中对其进行了24小时和48小时的浓度-抑制率相关曲线测定(图2a和图2b)
其中,图2a和图2b中横坐标分别为Iressa和喹唑啉衍生物1a的不同浓度(1-5μM)和不同作用时间{24小时和48小时(24 hours and 48 hours)},纵坐标为Iressa和化合物1a分别作用于对Iressa不敏感的肺癌细胞NCI-H1975和A549时的抑制率(%,Inhibition Rate)。
具体实施方式
通过下述实施例将有助于理解本发明,但并不能限制本发明的内容。
实施例1
在10mL微波反应管(微波反应器采用CEM公司生产的Discover型号环形聚焦单模微波合成仪)中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和2-溴,5-三氟甲基苯胺(39mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,二氯甲烷/甲醇(CH2Cl2/MeOH)(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(40mg,74%)。
熔点M.p.178-180℃.
红外光谱IR(KBr):3407,2937,2758,1622,1538,1456,1434,1324,1258,1128,1025,927.1,508.2cm-1.
氢谱1H NMR(MeOD,400MHz):δ9.26(s,1H),8.77(s,1H),7.90(brs,1H),7.73(d,J=7.6Hz,1H),7.31(s,1H),7.22(d,J=7.6Hz,1H),7.07(s,3H),4.25(m,2H),4.04(s,3H),2.53(m,2H),2.43(m,4H),2.13(m,2H),1.60(m,4H),1.26(m,2H).
质谱EI-MS(m/z):538(M+).
元素分析理论值(Anal.calc.For)C24H26BrF3N4O2:C,53.44;H,4.86;N,10.39;实测值(Found):C,52.94;H,5.09;N,9.98.
实施例2
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和3,5-二三氟甲基苯胺(46mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(39mg,74%)。
M.p.156-158℃.
IR(KBr):2948,1636,1539,1515,1474,1419,1325,1179,1125,1072,948,888,731,682,593cm-1.
1H NMR(MeOD,300MHz):δ8.73(s,1H),8.55(s,2H),8.04(s,1H),7.77(s,1H),7.27(brs,1H),7.35(s,1H),4.33(brs,2H),4.08(s,3H),3.61(d,J=2.2Hz,2H),3.35(brs,2H),3.02(brs,2H),2.44(s,2H),2.39(brs,2H),1.86(m,2H),1.568(m,1H).
EI-MS(m/z):528.9(M+).
Anal.calc.for C25H28F6N4O3·H2O:C,54.94;H,5.16;N,10.25;Found C,55.33;H,5.64;N,9.92.
实施例3
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和2-氟,5-三氟甲基苯胺(36mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(33mg,68%)。
M.p.134-136℃.
IR(KBr):3734,2926,1622,1539,1456,1418,1386,1327,1237,1121,1067,844,599,659cm-1.
1H NMR(MeOD,300MHz):δ8.39(s,1H),8.08(d,J=0.5Hz,1H),7.75(s,1H),7.59(m,1H),7.44(t,J=0.5Hz,1H),7.16(s,1H),4.29(t,J=0.9Hz,2H),4.03(s,3H),3.32-3.25(m,8H),2.35(q,J=2.2Hz,2H),1.89(t,J=2.2Hz,4H),1.70(d,J=2.1Hz,2H).
EI-MS(m/z):479.0(M+H+).
Anal.calc.for C24H26F4N4O2·0.5H2O:C,59.13;H,5.58;N,11.49;Found:C,58.71;H,5.95;N,11.07.
实施例4
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和4-溴,5-三氟甲基苯胺(39mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(40mg,74%)。
M.p.149-151℃.
IR(KBr):3325,2936,1625,1577,1507,1423,1318,1239,1176,1141,1018,849,668cm-1.
1H NMR(MeOD,300MHz):δ10.58(s,1H),10.19(t,J=1.1Hz,1H),8.88(s,1H),8.64(s,1H),7.67(s,1H),8.17(d,J=1.1Hz,1H),7.98(d,J=1.1Hz,1H),7.49(s,1H),4.30(s,2H),4.07(s,3H),3.21(s,2H),2.91(d,J=1.8Hz,2H),2.36(d,J=2.3Hz,2H),1.81-1.41(m,6H).
Anal.calc.for C24H26BrF3N4O2:C,53.44;H,4.86;N,10.39;Found:C,53.33;H,4.77;N,9.97.
EI-MS(m/z):538(M+).
实施例5
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和2-氯,5-三氟甲基苯胺(40mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(40mg,81%)。
M.p.169-170℃.
IR(KBr):2930,2854,1622,1573,1508,1242,1129cm-1.
1H NMR(300MHz,CDCl3):δ9.24(brs,1H),8.77(s,1H),7.84(s,1H),7.57(d,2H,J=9.0Hz),7.32-7.27(m,2H),7.04(s,1H),4.24(t,2H,J=6.6Hz),4.04(s,3H),2.55-2.42(m,6H),2.17-2.08(m,2H),1.63-1.56(m,4H),1.48-1.44(m,2H).
ESI-MS(m/z):495(M+H)+.
Anal.calc.for C24H26ClF3N4O2:C,58.24;H,5.29;N,11.32;Found C,57.91;H,5.30;N,11.17.
实施例6
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和3-三氟甲基苯胺(32mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(36mg,79%)。
M.p.90-92℃.
IR(KBr):3574,2937,1627,1496,1332,1124cm-1.
1H NMR(300MHz,CD3Cl):δ8.67(s,1H),8.00-7.98(m,2H),7.70(s,1H),7.46(t,J=8.1Hz,1H),7.38-7.36(m,1H),7.24(s,1H),7.14(s,1H),4.15(t,J=6.6Hz,2H),3.95(s,3H),2.51-2.40(m,6H),2.10-2.05(m,2H),1.60-1.54(m,4H),1.44-1.43(m,2H).
ESI-MS(m/z):461(M+H)+.
Anal.calc.for C24H27F3N4O2·0.5H2O:C,61.40;H,6.01;N,11.93;Found C,61.73;H,6.04;N,11.85.
实施例7
在10mL微波反应管中加入4-氯,6-甲氧基,7-(3-哌啶代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(1mL),加入浓盐酸(0.1mL)和2-三氟甲基苯胺(32mg,0.2mmol),微波反应器中反应(150w,125℃,5分钟)。浓缩,CH2Cl2/MeOH(10∶1,20mL)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(26mg,74%)。
M.p.191-193℃.
IR(KBr):3611,2624,1629,1525,1315,1261,1121cm-1.
1H NMR(300MHz,CD3OD):δ8.20(s,1H),7.83-7.70(m,3H),7.57-7.55(m,2H),7.15(s,1H),4.20(t,J=6Hz,2H),3.99(s,3H),2.64-2.52(m,6H),2.14-2.09(m,2H),1.67-1.60(m,4H),1.50-1.49(m,2H).
ESI-MS(m/z):461(M+H)+
Anal.calc.for C24H27F3N4O2·0.5H2O:C,61.40;H,6.01;N,11.93;found C,61.07;H,6.14;N,11.91.
实施例8
4-(2’-氯-5’-三氟甲基苯胺基),6-甲氧基,7-羟基喹唑啉(19mg,0.05mmol),PPh3(39mg,0.15mmol)置于25mL蛋形瓶中,抽换氮气三次,氮气保护下加入干燥CH2Cl2,3-吗啉,1-丙醇(10mg,0.07mmol),DEAD(26mg,0.15mmol),室温下搅拌过夜。浓缩,残余物经柱层析分离纯化得到白色固体(7mg,37%)。
M.p.212-214℃.
IR(KBr):3609,3630,2955,1578,1321,1280,1170,1118,922,774,668,500cm-1.
1H NMR(MeOD,400MHz):δ8.34(s,1H),8.00(d,J=11.2Hz,1H),7.87(s,1H),7.71-7.69(m,2H),7.16(s,1H),4.23(t,J=8.4Hz,2H),3.74(s,3H),3.74-3.69(m,6H),2.65(t,J=9.6Hz,2H),2.57-2.52(m,6H),1774-1.725(m,2H).EI-MS(m/z):496.1(M+).
碳谱13C NMR(MeOD/CDCl3,75MHz):δ164.9,158.2,153.9,149.6,147.8,139.7,132.5,132.1,131.3,118.9,112.8,109.3,74.8,67.9,59.8,58.5,56.0,47.9.
高分辨质谱HRMS(ESI)calcd for C23H24ClN4O3F3(M+):496.1489;found:496.1489.
实施例9
在4-氯,6-甲氧基,7-(3-环己烷代丙氧基)喹唑啉(26mg,0.1mmol)的异丙醇溶液(2mL)中,加入浓盐酸(0.1mL)和2,氯-5,三氟甲基苯胺(34mg,0.1mmol),回流6小时。浓缩,CH2Cl2/MeOH(10∶1)和水萃取。有机相依次用水和饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,残余物经柱层析分离,得到白色固体(40mg,71%)。
M.p.134-136℃.
IR(KBr):3429,2922,2852,1619,1528,1321,1278,1122,842,503cm-1.
1H NMR(CDCl3,300MHz):δ8.61(s,1H),7.45(s,1H),7.22(2H,d,J=8.8Hz),7.16(s,1H),6.83(d,J=8Hz,2H),4.51(h,J=6.0Hz,1H),4.37-4.28(m,4H),4.48-4.20(m,4H),4.00(s,3H),3.82-3.74(m,4H),3.32-3.23(m,6H),1.84-1.50(m,6H),1.27(s,3H),1.26(s,3H),1.80-0.96(m,1H).EI-MS(m/z):494.2(M+H+).
Anal.calc.for C25H27ClF3N3O2:C,60.79;H,5.51;N,8.51;Found:C,60.70;H,5.58;N,8.41.
实施例10
4-(2’-氯-5’-三氟甲基,N-叔丁氧羰基苯胺基),6-甲氧基,7-羟基喹唑啉(47mg,0.1mmol)和烯丙基溴(24mg,0.2mmol),K2CO3(64mg,0.5mmol),丙酮(10mL)置于25mL蛋形瓶中,回流5小时,过滤,浓缩,残余物经柱层析分离,得到黄色固体(22mg,52%)。
M.p.122-124℃.
IR(KBr):2929,1622,1522,1486,1322,1277,1122,1078,1044,882,823,706cm-1.
1H NMR(MeOD,400MHz):8.24-8.12(m,1H),7.80(s,1H),7.65-7.61(m,2H),7.58(s,1H),5.38(d,J=10.0Hz,1H),6.02(d,J=6Hz,1H),3.97(s,3H).
EI-MS(m/z):432.0(M+Na+).
Anal.calc.for C19H15ClF3N3O2:C,55.69;H,3.69;N,10.25;Found:C,55.27;H,4.05;N,9.83.
实施例11
4-(2’-氯-5’-三氟甲基,N-叔丁氧羰基苯胺基),6-甲氧基,7-羟基喹唑啉(47mg,0.1mmol)和3-四氮唑,1-溴丙烷(38mg,0.2mmol),K2CO3(64mg,0.5mmol),丙酮(10mL)置于25mL蛋形瓶中,回流5小时,过滤,浓缩,残余物经柱层析分离,得到黄色固体(23mg,47%)。
M.p.118-120℃.
IR(KBr):3420,2929,1623,1522,1433,1415,1322,1278,1127,1080,1051,833,706cm-1.
1H NMR(MeOD,400MHz):δ8.41(s,1H),7.98(s,1H),7.56(s,1H),7.39(s,2H),7.30(s,1H),6.37(s,1H),4.59-4.56(m,2H),4.10(t,J=5.1Hz,2H),3.70(s,3H),2.33(dd,J=5.1Hz,2H).
13C NMR(MeOD,75MHz):δ156.2,154.0,153.0,149.0,137.6,131.2,129.0,126.801,126.8,125.4,124.2,124.2,102.9,101.6,100.4,55.1,49.8,27.2.EI-MS(m/z):452.9(M+).
HRMS(ESI)calcd for C19H20Cl F N7O5(M+):480.1171;found,80.1193.
实施例12
4-(2’-氯-5’-三氟甲基,N-叔丁氧羰基苯胺基),6-甲氧基,7-羟基喹唑啉(47mg,0.1mmol)和2,哌啶基甲磺酸乙酯(41mg,0.2mmol),K2CO3(64mg,0.5mmol),丙酮(10mL)置于25mL蛋形瓶中,回流5小时,过滤,浓缩,残余物经柱层析分离,得到黄色固体(22mg,46%)。
M.p.148-150℃.
IR(KBr):2934,2853,1621,1520,415,1321,1169,1122,1079,824,705cm-1.
1H NMR(MeOD,400MHz):8.21(s,1H),7.84(s,1H)。7.69(s,2H),7.59(s,1H),6.69(s,1H),4.33(t,J=7.6Hz,2H),3.99(s,3H),2.76(t,J=8.0Hz,2H),2.47-2.45(m,4H),1.56-1.54(m,4H),1.46-1.45(m,2H).
EI-MS(m/z):481.3(M+H+).
13C NMR(d5-Pyridine,75MHz):δ157.0,155.7,152.3,150.1,136.2,130.205,129.0,127.4,126.3,126.3,126.0,114.7,110.5,103.8,58.6,57.9,56.8,49.4,28.2,26.4.
HRMS(ESI)calcd for C20H25ClFN7O4(M+):481.1619;found,481.1635.
实施例13
4-(2’-氯-5’-三氟甲基,N-叔丁氧羰基苯胺基),6-甲氧基,7-羟基喹唑啉(47mg,0.1mmol)和3-叠氮基,1-碘丙烷(42mg,0.2mmol),K2CO3(64mg,0.5mmol),丙酮(10mL)置于25mL蛋形瓶中,回流5小时,过滤,浓缩,残余物经柱层析分离,得到黄色固体(17mg,38%)。
M.p.115-117℃.
IR(KBr):2927,2099,1618,1521,1490,1321,1275,1225,1169,1121,1079,824cm-1.
1HNMR(CDCl3,400MHz):7.92(s,1H),7.81(s,1H),7.69(s,1H),7.55(d,J=8.0Hz,1H),7.48(d,J=8.0Hz,1H),6.59(s,1H),4.07(m,2H),3.73(s,3H),3.35(t,J=6.0Hz,2H),1.99-1.97(m,2H).
EI-MS(m/z):452.9(M+).
13C NMR(CDCl3,75MHz):δ155.3,152.6,147.9,136.5,130.0,125.2,124.4,121.6,104.5,103.8,100.1,55.9,48.1,47.8,27.1.
HRMS(ESI)calcd for C19H20Cl F N7O5(M+):453.1053;found:453.1048.
实施例14
将化合物1e(100mg)置于氯化氢的饱和乙酸乙酯溶液中(10ml),在室温下搅拌2小时。将沉淀分离,用乙酸乙酯洗涤并干燥。因此得到化合物1e的二盐酸盐(114mg)。
1H NMR(MeOD,400MHz):8.68(s,1H),8.04(s,1H),7.97(s,1H),7.81-7.80(m,2H),7.33(s,1H),4.43(m,2H),4.09(s,3H),3.66(m,2H),3.39(m,2H),3.01(m,2H),2.43(2H,m),1.98-1.87(m,8H).
Anal.calc.for C24H26ClF3N4O22HCl:C,50.76;H,4.97;N,9.87;Found:C,50.38;H,5.30;N,9.74.
实施例15
1、对Iressa不敏感的肺癌细胞NCI-1975和A549,调整细胞悬液浓度至5×104cells/ml,96孔板每孔加入100ul,铺板使待测细胞数至5000个/孔,边缘孔用无菌PBS填充;
2.、5%CO2,37℃孵育,至细胞贴壁后(6小时或过夜),加入浓度梯度的药物,设6个浓度梯度,每孔追加10ul,10倍稀释药物至所设浓度,设3个复孔;
3.、5%CO2,37℃孵育24或48小时,倒置显微镜下观察;
4、每孔加入10ulMTT(1∶10稀释)溶液,继续培养4h;
5、终止培养,小心吸去孔内培养液;
6、每孔加入150ul二甲基亚砜(DMSO),振荡2min,使结晶物充分溶解。在酶联免疫检测仪OD490nm处测量各孔的吸光值;
7、同时设置单加培养基,不加细胞的空白对照;
8、计算抑制率及半数抑制浓度。
注:实验中使用Iressa和阿霉素(Adriamycin)作为阳性对照,实施例15实验结果如附图1和2。
图1显示本发明的部分喹唑啉衍生物的抗癌活性的结果,其中横坐标为喹唑啉衍生物标号,喹唑啉衍生物1a、1b、1c和1d分别对应于实施例1、2、4和5,纵坐标为喹唑啉衍生物作用于对Iressa不敏感的肺癌细胞NCI-H1975时的IC50(μM)(半数抑制浓度)值。喹唑啉衍生物1a、1b、1c和1d具有如下的结构式:
图2显示本发明的喹唑啉衍生物1a和Iressa分别在对Iressa不敏感的肺癌细胞NCI-H1975和A549中对其进行了24小时和48小时的浓度-抑制率相关曲线测定(图2a和图2b)
其中,图2a和图2b中横坐标分别为Iressa和喹唑啉衍生物1a的不同浓度(1-5μM)和不同作用时间{24小时和48小时(24 hours and 48 hours)},纵坐标为Iressa和化合物1a分别作用于对Iressa不敏感的肺癌细胞NCI-H1975和A549时的抑制率(%,Inhibition Rate)。
实验结果显示,本发明中的部分喹唑啉衍生物对Iressa不敏感的细胞NCI-H1975和A549显示了良好的抑制作用。
Claims (7)
1.一种喹唑啉衍生物或其药用盐,该喹唑啉衍生物具有如下的结构式:
其中,n为1,2或3;R1为C1-4的烷氧基;R2各自独立地代表卤素、三氟甲基、C1-4的烷氧基或C1-4的烷氧羰基;R3为二-{C1-4的烷基-C2-4的烷氧基、吡咯烷-1-基-C2-4的烷氧基、哌啶子基-C2-4的烷氧基、吗啉代-1-基-C2-4的烷氧基、哌嗪-1-基-C2-4的烷氧基、4-C1-4的烷基哌嗪-1-基-C2-4的烷氧基、咪唑-1-基-C2-4的烷氧基、二-[C 1-4的烷氧基-C2-4的烷氧基]氨基-C2-4的烷氧基、硫吗啉代-C2-4的烷氧基、1-氧代硫吗啉代-C2-4的烷氧基、1,1-二氧代硫吗啉代-C2-4的烷氧基、烯丙氧基或叠氮子基-C2-4的烷氧基;
所述的喹唑啉衍生物药用盐是上述喹唑啉衍生物的盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、三氟乙酸盐、枸橼酸盐、马来酸盐、酒石酸盐、富马酸盐、甲磺酸盐或4-甲苯磺酸盐。
3.一种喹唑啉衍生物或其药用盐的制备方法,其特征是通过下述(a)或(b)两种步骤获得喹唑啉衍生物,或者采用(a)和(c),或(b)和(c)两种步骤获得喹唑啉衍生物的药用盐:
(a)有机溶剂溶剂中和微波下,结构式为的喹唑啉衍生物,结构式为的苯胺和催化量的浓盐酸反应1-30分钟;所述的结构式(2)的喹唑啉化合物、结构式(3)的苯胺的摩尔比为1∶1~2;所述的Z为具有离去性能的取代基,包括氯原子、溴原子、碘原子、甲氧基、苯氧基、甲磺酰基或甲苯-4-璜酰氧基;
(b)在室温下和有机溶剂中,结构式的喹唑啉化合物、三苯基膦、偶氮二甲酸二乙酯或偶氮二甲酸二异丙酯、与醇反应2-10小时;所述的喹唑啉化合物、三苯基膦、偶氮二甲酸二乙酯或偶氮二甲酸二异丙酯、和醇的摩尔比为1∶1~5∶1~5∶1~5;所述的醇为吗啉代-(C2-4)醇(或哌嗪-1-基-(C2-4)醇、4-(C1-4)烷基哌嗪-1-基-(C2-4)醇、咪唑-1-基-(C2-4)醇、二-[(C 1-4)烷氧基-(C2-4)烷氧基]氨基-(C2-4)醇、硫吗啉代-(C2-4)醇、1-氧代硫吗啉代-(C2-4)醇或1或1-二氧代硫吗啉代-(C2-4)的醇;
(c)有机溶剂中,将步骤(a)或(b)获得的喹唑啉化合物分别和酸反应10-60分钟;所述的喹唑啉化合物与酸的摩尔比为1∶1~100;所述的酸为盐酸、氢溴酸、硫酸、磷酸、三氟乙酸、枸橼酸、马来酸、酒石酸、富马酸、甲磺酸或4-甲苯磺酸;
其中,n、R1、R2和R3如权利要求1所述;Z为具有离去性能的取代基,包括氯原子、溴原子、碘原子、甲氧基、苯氧基、甲磺酰基或甲苯-4-璜酰氧基。
4.如权利要求3的喹唑啉衍生物或其药用盐的制备方法,其特征是所述的有机溶剂是甲醇、乙醇、正丙醇、正丁醇、异丙醇、二氯甲烷、氯仿、1,2-二氯乙烷、四氯化碳、乙醚、四氢呋喃、苯、甲苯、二甲苯、丙酮、丁酮、乙腈、N,N-二甲基甲酰胺或二甲亚砜。
5.如权利要求3的喹唑啉衍生物或其药用盐的制备方法,其特征是所述的微波波长为1毫米到1米,功率为10瓦到300瓦。
6.一种如权利要求1的喹唑啉衍生物或其药用盐用于制备治疗肺癌的药物。
7.如权利要求5所述的的喹唑啉衍生物或其药用盐的用途,其特征是所述的肺癌为非小细胞肺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101824265A CN101838245B (zh) | 2010-05-21 | 2010-05-21 | 喹唑啉衍生物或其药用盐、制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101824265A CN101838245B (zh) | 2010-05-21 | 2010-05-21 | 喹唑啉衍生物或其药用盐、制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101838245A true CN101838245A (zh) | 2010-09-22 |
CN101838245B CN101838245B (zh) | 2012-07-25 |
Family
ID=42741951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101824265A Expired - Fee Related CN101838245B (zh) | 2010-05-21 | 2010-05-21 | 喹唑啉衍生物或其药用盐、制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101838245B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102267952A (zh) * | 2011-06-21 | 2011-12-07 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
CN103288756A (zh) * | 2012-02-29 | 2013-09-11 | 江苏先声药物研究有限公司 | 一种喹唑啉中间体的甲醇溶剂合物及其制备方法 |
WO2016023330A1 (zh) * | 2014-08-11 | 2016-02-18 | 石药集团中奇制药技术(石家庄)有限公司 | 喹唑啉衍生物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101347433A (zh) * | 2007-07-20 | 2009-01-21 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的制药用途 |
-
2010
- 2010-05-21 CN CN2010101824265A patent/CN101838245B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101347433A (zh) * | 2007-07-20 | 2009-01-21 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的制药用途 |
Non-Patent Citations (1)
Title |
---|
《中国博士学位论文全文数据库 工程科技I辑》 20080715 章砚东 喹唑啉类化合物库的固相合成、生物活性筛选及钐试剂在有机合成中的应用 第23页 1-2 , 第7期 2 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102267952A (zh) * | 2011-06-21 | 2011-12-07 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
CN102267952B (zh) * | 2011-06-21 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
CN103288756A (zh) * | 2012-02-29 | 2013-09-11 | 江苏先声药物研究有限公司 | 一种喹唑啉中间体的甲醇溶剂合物及其制备方法 |
CN103288756B (zh) * | 2012-02-29 | 2016-04-20 | 江苏先声药物研究有限公司 | 一种喹唑啉中间体的甲醇溶剂合物及其制备方法 |
WO2016023330A1 (zh) * | 2014-08-11 | 2016-02-18 | 石药集团中奇制药技术(石家庄)有限公司 | 喹唑啉衍生物 |
US10421754B2 (en) | 2014-08-11 | 2019-09-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Quinazoline derivative |
RU2704125C2 (ru) * | 2014-08-11 | 2019-10-24 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Производные хиназолина |
US10774079B2 (en) | 2014-08-11 | 2020-09-15 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Quinazoline derivative |
Also Published As
Publication number | Publication date |
---|---|
CN101838245B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Development of selective mono or dual PROTAC degrader probe of CDK isoforms | |
JP6889689B2 (ja) | プロテインキナーゼコンジュゲート及びインヒビター | |
ES2647416T3 (es) | Inhibidores de PI3K delta selectivos | |
Zhang et al. | Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors | |
Wang et al. | Design, synthesis, biological evaluation and molecular docking study of novel thieno [3, 2-d] pyrimidine derivatives as potent FAK inhibitors | |
CN107072985A (zh) | 治疗性抑制化合物 | |
BR112013017670B1 (pt) | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas | |
CN104693257B (zh) | 苯磺酰基呋咱修饰的吉西他滨衍生物及其制备方法和用途 | |
Reddy et al. | Biscoumarin–pyrimidine conjugates as potent anticancer agents and binding mechanism of hit candidate with human serum albumin | |
Girgis et al. | 3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2 | |
CN101838245B (zh) | 喹唑啉衍生物或其药用盐、制备方法和用途 | |
US20190084988A1 (en) | Wdr5 inhibitors and modulators | |
WO2012073184A1 (en) | Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases | |
Zhang et al. | Discovery of 3-(((9H-purin-6-yl) amino) methyl)-4, 6-dimethylpyridin-2 (1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer | |
Li et al. | Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing | |
Hamajima et al. | Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors | |
Chen et al. | Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer | |
Yang et al. | Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4 (3H)-one derivatives as potential anticancer agents via PI3K inhibition | |
CN113045559B (zh) | 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用 | |
Hu et al. | Design, synthesis and biological evaluation of novel 2, 4-diaminopyrimidine derivatives as potent antitumor agents | |
CN107266466A (zh) | 灯盏乙素生物素标记探针的应用及相关pkm2激酶抑制剂 | |
Premsagar Miriyala et al. | Design, Synthesis and Cytotoxicity of New Coumarin‐1, 2, 3‐triazole Derivatives: Evaluation of Anticancer Activity and Molecular Docking Studies | |
Liu et al. | Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor | |
CN108358927A (zh) | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 | |
TW201738227A (zh) | 一種稠環化合物、其製備方法和應用及其中間體化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120725 Termination date: 20150521 |
|
EXPY | Termination of patent right or utility model |